Patient and transplantation characteristics
| Factors . | Single . | Double . | P . |
|---|---|---|---|
| Total | 80 | 185 | |
| Year at transplantation | < .01 | ||
| 1994-1997 | 7 (8%) | 0 | |
| 1998-2000 | 23 (29%) | 2 (1%) | |
| 2001-2003 | 39 (49%) | 64 (35%) | |
| 2004-2005 | 11 (14%) | 99 (54%) | |
| 2006 (first half) | 0 | 20 (10%) | |
| Recipient age at transplantation | |||
| 10-18 | 35 (44%) | 23 (12%) | < .01 |
| ≥ 18 | 45 (56%) | 162 (88%) | |
| Median (range) | 23 (10-65) | 45 (10-69) | < .01 |
| Recipient weight at transplantation, median (range) | 63 (30-107) | 78 (33-149) | < .01 |
| Recipient sex | .08 | ||
| Male | 40 (50%) | 114 (62%) | |
| Female | 40 (50%) | 71 (38%) | |
| Recipient CMV serostatus | .38 | ||
| Negative | 41 (51%) | 84 (45%) | |
| Positive | 39 (49%) | 101 (55%) | |
| Recipient diagnosis | .28 | ||
| ALL | 16 (20%) | 31 (17%) | |
| AML | 30 (38%) | 67 (36%) | |
| CML | 6 (7%) | 10 (5%) | |
| MDS | 7 (9%) | 13 (7%) | |
| NHL | 7 (9%) | 31 (17%) | |
| Other malignancies | 3 (3%) | 18 (10%) | |
| Aplastic anemia | 4 (5%) | 8 (4%) | |
| Metabolic disorder | 7 (9%) | 7 (4%) | |
| Disease risk | .29 | ||
| Standard | 35 (44%) | 94 (51%) | |
| High | 45 (56%) | 91 (49%) | |
| HLA match (lowest)* | .98 | ||
| 6/6 | 7 (9%) | 15 (8%) | |
| 5/6 | 28 (35%) | 64 (35%) | |
| 4/6 | 45 (56%) | 106 (57%) | |
| HLA match (engrafting unit)† | .87 | ||
| 6/6 | 7 (9%) | 13 (7%) | |
| 5/6 | 28 (35%) | 68 (37%) | |
| 4/6 | 45 (56%) | 104 (56%) | |
| Conditioning | < .01 | ||
| Myeloablative | 61 (76%) | 78 (42%) | |
| Nonmyeloablative | 19 (24%) | 107 (58%) | |
| Use of ATG in the conditioning | < .01 | ||
| Yes | 46 (58%) | 49 (26%) | |
| No | 34 (43%) | 136 (74%) | |
| GVHD prophylaxis | < .01 | ||
| CSA/MP | 46 (58%) | 4 (2%) | |
| CSA/MMF | 33 (41%) | 181 (98%) | |
| CSA/MTX | 1 (1%) | 0 | |
| Total nucleated cell dose, (×107/kg recipient), median (range) | 2.4 (0.9-14.0) | 3.6 (1.1-8.0) | < .01 |
| Total CD34 cell dose (×105/kg recipient), median (range) | 2.8 (0.5-1.9) | 4.7 (0.7-1.7) | < .01 |
| Total CD3 cell dose (×104/kg recipient), median (range) | 0.6 (0.1-56.4) | 1.3 (0.1-3.1) | < .01 |
| Follow-up among survivors, median (range) in years | 4.8 (2.0-9.2) | 2.2 (1.0-5.3) |
| Factors . | Single . | Double . | P . |
|---|---|---|---|
| Total | 80 | 185 | |
| Year at transplantation | < .01 | ||
| 1994-1997 | 7 (8%) | 0 | |
| 1998-2000 | 23 (29%) | 2 (1%) | |
| 2001-2003 | 39 (49%) | 64 (35%) | |
| 2004-2005 | 11 (14%) | 99 (54%) | |
| 2006 (first half) | 0 | 20 (10%) | |
| Recipient age at transplantation | |||
| 10-18 | 35 (44%) | 23 (12%) | < .01 |
| ≥ 18 | 45 (56%) | 162 (88%) | |
| Median (range) | 23 (10-65) | 45 (10-69) | < .01 |
| Recipient weight at transplantation, median (range) | 63 (30-107) | 78 (33-149) | < .01 |
| Recipient sex | .08 | ||
| Male | 40 (50%) | 114 (62%) | |
| Female | 40 (50%) | 71 (38%) | |
| Recipient CMV serostatus | .38 | ||
| Negative | 41 (51%) | 84 (45%) | |
| Positive | 39 (49%) | 101 (55%) | |
| Recipient diagnosis | .28 | ||
| ALL | 16 (20%) | 31 (17%) | |
| AML | 30 (38%) | 67 (36%) | |
| CML | 6 (7%) | 10 (5%) | |
| MDS | 7 (9%) | 13 (7%) | |
| NHL | 7 (9%) | 31 (17%) | |
| Other malignancies | 3 (3%) | 18 (10%) | |
| Aplastic anemia | 4 (5%) | 8 (4%) | |
| Metabolic disorder | 7 (9%) | 7 (4%) | |
| Disease risk | .29 | ||
| Standard | 35 (44%) | 94 (51%) | |
| High | 45 (56%) | 91 (49%) | |
| HLA match (lowest)* | .98 | ||
| 6/6 | 7 (9%) | 15 (8%) | |
| 5/6 | 28 (35%) | 64 (35%) | |
| 4/6 | 45 (56%) | 106 (57%) | |
| HLA match (engrafting unit)† | .87 | ||
| 6/6 | 7 (9%) | 13 (7%) | |
| 5/6 | 28 (35%) | 68 (37%) | |
| 4/6 | 45 (56%) | 104 (56%) | |
| Conditioning | < .01 | ||
| Myeloablative | 61 (76%) | 78 (42%) | |
| Nonmyeloablative | 19 (24%) | 107 (58%) | |
| Use of ATG in the conditioning | < .01 | ||
| Yes | 46 (58%) | 49 (26%) | |
| No | 34 (43%) | 136 (74%) | |
| GVHD prophylaxis | < .01 | ||
| CSA/MP | 46 (58%) | 4 (2%) | |
| CSA/MMF | 33 (41%) | 181 (98%) | |
| CSA/MTX | 1 (1%) | 0 | |
| Total nucleated cell dose, (×107/kg recipient), median (range) | 2.4 (0.9-14.0) | 3.6 (1.1-8.0) | < .01 |
| Total CD34 cell dose (×105/kg recipient), median (range) | 2.8 (0.5-1.9) | 4.7 (0.7-1.7) | < .01 |
| Total CD3 cell dose (×104/kg recipient), median (range) | 0.6 (0.1-56.4) | 1.3 (0.1-3.1) | < .01 |
| Follow-up among survivors, median (range) in years | 4.8 (2.0-9.2) | 2.2 (1.0-5.3) |
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia, CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; and NHL, non-Hodgkin lymphoma.
High risk refers to acute leukemia in CR1 and CR2, CML in first chronic phase, and MDS without excess blasts or nonmalignant diseases. Standard risk refers to all others.
HLA match equals the poorest matched unit in recipients of two UCB units.
HLA match (engrafting unit) equals the HLA match of units that engrafted long term.